Proportion of effective responders, crossover injection, patients who underwent spinal surgery, and adverse events between the dexamethasone and betamethasone groups

Primary/secondary endpoint Dexamethasone (n = 200) Betamethasone (n = 216) Risk difference
(95% confidence interval)
Risk ratio
(95% confidence interval)
Odds ratio
(95% confidence interval)
P value
Primary endpoint
Effective responders 63 (31.5) 72 (33.3) –1.83 (–10.83, 7.16) 1.04 (0.86, 1.26) 1.09 (0.71, 1.68) 0.670
Secondary endpoint
Crossover injection 125 (62.5) 141 (65.3) –2.81 (–12.08, 6.45) 1.06 (0.87, 1.29) 1.13 (0.74, 1.72) 0.551
Having spinal surgery 16 13 1.98 (–2.93, 6.90) 0.85 (0.56, 1.29) 0.74 (0.32, 1.68) 0.428
Adverse events 40 (20.0) 24 (11.1) 8.89 (1.93, 15.84) 0.69 (0.49, 0.96) 0.50 (0.28, 0.89) 0.012*

Values are presented as number (%) or number only.

*Statistically significant when the P value was less than 0.05.

Korean J Pain 2022;35:336~344 https://doi.org/10.3344/kjp.2022.35.3.336
© Korean J Pain